Advancing Gene Therapy Research for Hemophilia A at MCW
Kristi Castello, Division Administrator III at the Medical College of Wisconsin, reposted from Medical College of Wisconsin on LinkedIn:
Quoting Medical College of Wisconsin‘s post:
”For people with hemophilia A, a simple cut or bump can cause excessive bleeding or bruising. While treatments exist to replace this protein, patients may form antibodies to the current therapies.
For more than two decades, MCW’s David A. Wilcox, PhD has worked with colleagues to develop a new gene therapy that could transform how patients with the disease are treated.
The team has completed preliminary studies of a Phase 1 clinical trial at MCW, ran by MCW’s Dr. Mary Eapen, with a gene therapy that genetically-modifies a patient’s own bone marrow cells to make a blood clotting factor.
Learn more:”
Stay updated with Hemostasis Today.
-
Nov 14, 2025, 11:58Marilena Vrana: Can Public-only Blood Collection Systems Meet the Growing Patient Need for PDMs?
-
Nov 14, 2025, 11:48Cedric Hermans Shares the 1st Illustrated Review Dedicated to Hemophilia B
-
Nov 14, 2025, 10:28Valance Washington: Proud to Share Our Lab’s Latest Publication in Platelets Journal
-
Nov 14, 2025, 10:18Sripal Bangalore and Ajay Kirtane on TUXEDO-2 Comparison Focusing on Diabetic Patients
-
Nov 14, 2025, 10:11Ashley Lawrenson on Her Coagulation Journey Using Automation With the HemoCell and HemoHub
-
Nov 14, 2025, 10:05Kingsley Wheaton: A Year Ago, Omni Was an Idea – Today, It’s a Movement!
-
Nov 14, 2025, 09:58Rucha Patil Takes The National DHR-ICMR Gold Award for Best Technology
-
Nov 14, 2025, 09:48Caitlin Raymond on ”The Plasma Chasers”
-
Nov 14, 2025, 09:42Erin VanDyke on Why They Do In-person Site Visits for NBCA Centers of Excellence Designation!